Core Viewpoint - The company reported positive results from its ASC30 oral small molecule GLP-1 receptor agonist in a clinical trial, highlighting its efficacy and safety for obesity treatment [1] Group 1: Clinical Trial Details - The ASC30 study is a Phase Ib multi-dose escalation (MAD) trial conducted in the United States, focusing on safety, tolerability, pharmacokinetics, and preliminary efficacy in obese subjects with a BMI of 30-40 kg/m² [1] - The trial is randomized, double-blind, and placebo-controlled, ensuring robust data collection and analysis [1] Group 2: Future Expectations - The company anticipates reporting the top-line results of the 13-week Phase IIa study of ASC30 in the fourth quarter of this year [1] - The CEO emphasized the strong research and development capabilities of the company, aiming to provide differentiated treatment options for obesity [1]
歌礼制药-B(01672.HK)在第61届欧洲糖尿病研究协会(EASD)年会上报告其ASC30口服小分子GLP-1R激动剂28天多剂量递增研究队列1和队列2的结果